Literature DB >> 7389061

Evaluation of antitumor drug side effects in small animals.

W T Bradner, J E Schurig, J B Huftalen, G J Doyle.   

Abstract

This is an initial report on the development of screening tests for side effects of antitumor drugs, with small amounts of compound and short time intervals. These tests are based on acute dosing of mice and various blood or serum measurements: (a) total white blood cell count for leukopenia; (b) BUN for kidney toxicity; (c) SGPT for liver toxicity; and (d) creatine phosphokinase MB isozyme (CPK-MB) for cardiotoxicity. A correlation with the toxicity observed in other species is developed by establishing the effect of a prototype compound for each toxicity and tests of one or more compounds expected to lack such toxicity. On the basis of the limited number of compounds studied all four tests, although varying in sensitivity, seem to correlate with the results of tests in other species and with known effects in man. Final validation of these acute tests, especially the CPK-MB, will require both further study of histopathologic effects and correlation with results from clinical trials of an extended list of agents.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7389061     DOI: 10.1007/bf00254029

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  New manual and automated method for determining activity of creatine kinase isoenzyme MB, by use of dithiothreitol: clinical applications.

Authors:  P S Rao; J J Lukes; S M Ayres; H Mueller
Journal:  Clin Chem       Date:  1975-10       Impact factor: 8.327

2.  Adaptation of orbital bleeding technic to rapid serial blood studies.

Authors:  V RILEY
Journal:  Proc Soc Exp Biol Med       Date:  1960 Aug-Sep

3.  Subacute cardiotoxicity of adriamycin in the rat: biochemical and ultrastructural investigations.

Authors:  H M Olson; C C Capen
Journal:  Lab Invest       Date:  1977-10       Impact factor: 5.662

4.  Preclinical toxicologic evaluation of bleomycin (NSC 125 066), a new antitumor antibiotic.

Authors:  G R Thompson; J R Baker; R W Fleischman; H Rosenkrantz; U H Schaeppi; D A Cooney; R D Davis
Journal:  Toxicol Appl Pharmacol       Date:  1972-08       Impact factor: 4.219

5.  Delayed toxicity of 4'-demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) in mice.

Authors:  T L Avery; D Roberts; R A Price
Journal:  Cancer Chemother Rep       Date:  1973-04

6.  Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC-119875) in the male rat.

Authors:  R J Kociba; S D Sleight
Journal:  Cancer Chemother Rep       Date:  1971-02

7.  Adriamycin-induced cardiac damage in the mouse: a small-animal model of cardiotoxicity.

Authors:  S H Rosenoff; H M Olson; D M Young; F Bostick; R C Young
Journal:  J Natl Cancer Inst       Date:  1975-07       Impact factor: 13.506

8.  Chlorozotocin, 2-(3-(2-chloroethyl)-3-nitrosoureido)-D-glucopyranose, an antitumor agent with modified bone marrow toxicity.

Authors:  T Anderson; M G McMenamin; P S Schein
Journal:  Cancer Res       Date:  1975-03       Impact factor: 12.701

9.  Quantitative prediction of drug toxicity in humans from toxicology in small and large animals.

Authors:  M A Goldsmith; M Slavik; S K Carter
Journal:  Cancer Res       Date:  1975-05       Impact factor: 12.701

10.  Hematology and clinical chemistry reference values for C57BL/6 X DBA/2 F1 mice.

Authors:  S D Harrison; J A Burdeshaw; R G Crosby; A M Cusic; E P Denine
Journal:  Cancer Res       Date:  1978-08       Impact factor: 12.701

View more
  4 in total

1.  Antitumor activity and toxicity in animals of N-7[2-(4-nitrophenyldithio) ethyl] mitomycin C (BMY-25067).

Authors:  W T Bradner; W C Rose; J E Schurig; A P Florczyk
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

2.  Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine.

Authors:  J H Doroshow; G Y Locker; I Ifrim; C E Myers
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

3.  The mouse as a model for predicting the myelosuppressive effects of anticancer drugs.

Authors:  J E Schurig; A P Florczyk; W T Bradner
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Tallysomycin S10b: experimental antitumor activity and toxicity.

Authors:  J E Schurig; W C Rose; R S Hirth; A Schlein; J B Huftalen; A P Florczyk; W T Bradner
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.